Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, Z.
Right arrow Articles by Psyrri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, Z.
Right arrow Articles by Psyrri, A.
Clinical Cancer Research Vol. 11, 1160-1166, February 2005
© 2005 American Association for Cancer Research


Imaging, Diagnosis, Prognosis

Cyclin D1 Is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell Carcinoma

Ziwei Yu1, Paul M. Weinberger1, Bruce G. Haffty2, Clarence Sasaki1, Cynthia Zerillo3, John Joe1, Diane Kowalski4, James Dziura5, Robert L. Camp4, David L. Rimm4 and Amanda Psyrri3

Departments of 1 Otolaryngology, 2 Therapeutic Radiology, 3 Medical Oncology, 4 Pathology and 5 Biostatistics, Yale University School of Medicine, New Haven, Connecticut

Requests for reprints: Amanda Psyrri, Yale Cancer Center, P.O. Box 208032, New Haven, CT 06520. Phone: 203-737-2476; Fax: 203-785-7531; E-mail: diamando.psyrri{at}yale.edu.

Background: The current tumor-node-metastasis system is inadequate to accurately classify patients in terms of prognosis. Thus, with the availability of recently developed molecular tools, considerable interest lies in discovering prognostic markers in order to guide treatment decisions. In this study, we sought to determine the prognostic significance of the cell cycle regulator cyclin D1 in oropharyngeal squamous cell carcinoma (OSCC).

Experimental Design: We studied the protein expression levels of cyclin D1 on a tissue microarray composed of 63 OSCCs with long-term follow-up data available. Protein expression was analyzed with an automated in situ quantitative (AQUA) method which allows preservation of tissue morphology while quantifying protein expression in paraffin-embedded tissue.

Results: The mean follow-up time was 35 months. High cyclin D1 nuclear expression was associated with increased 5-year local recurrence rate (48% versus 15%), inferior 5-year disease-free survival (16% versus 58%), and inferior 5-year overall survival (17% versus 53%). In multivariate Cox regression, high nuclear cyclin D1 expression was an independent predictor for local recurrence, disease-free survival, and overall survival at 5 years.

Conclusions: Our results indicate that quantitative assessment of nuclear cyclin D1 expression level by automated in situ quantitative analysis is a strong predictor for outcome in OSCC. Thus, cyclin D1 may be a potential target for molecular intervention in patients with oropharyngeal squamous cell cancer.

Key Words: Head and neck cancer • Cell cycle checkpoints • Risk assessment • Proteomics




This article has been cited by other articles:


Home page
J. Mol. Diagn.Home page
I. Y. Cheung, Y. Feng, A. Vickers, W. Gerald, and N.-K. V. Cheung
Cyclin D1, a Novel Molecular Marker of Minimal Residual Disease, in Metastatic Neuroblastoma
J. Mol. Diagn., April 1, 2007; 9(2): 237 - 241.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A Psyrri, P Kountourakis, Z Yu, C Papadimitriou, S Markakis, R. Camp, T Economopoulos, and M. Dimopoulos
Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets
Ann. Onc., April 1, 2007; 18(4): 709 - 715.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
R. E. Brown, P. L. Zhang, M. Lun, S. Zhu, P. K. Pellitteri, A. Law, G. C. Wood, and T. L. Kennedy
Morphoproteomic and Pharmacoproteomic Rationale for mTOR Effectors as Therapeutic Targets in Head and Neck Squamous Cell Carcinoma
Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 273 - 282.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Psyrri, M. Kassar, Z. Yu, A. Bamias, P. M. Weinberger, S. Markakis, D. Kowalski, R. L. Camp, D. L. Rimm, and M. A. Dimopoulos
Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer
Clin. Cancer Res., December 15, 2005; 11(24): 8637 - 8643.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Psyrri, Z. Yu, P. M. Weinberger, C. Sasaki, B. Haffty, R. Camp, D. Rimm, and B. A. Burtness
Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis
Clin. Cancer Res., August 15, 2005; 11(16): 5856 - 5862.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2005 by the American Association for Cancer Research.